TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive NCI And SPORE PIs Discussing Potential Changes To Grant Program Guidelines. September 19, 2008
TCL Archive Britain’s Cancer Czar Begins Examination of Risks and Benefits of Mammography October 28, 2011
TCL Archive NCI Bypass Budget For FY 1992 Requests $2.6 Billion Support grows In Congress May 18, 1990
